Trimedyne Appeals To Antitrust Law To Counter Lumenis Infringement Claims
This article was originally published in The Gray Sheet
Executive Summary
Trimedyne is alleging unfair trade practices by Lumenis in countering the Israeli laser manufacturer's claims of patent infringement
You may also be interested in...
Litigation In Brief
Medinol v. Boston Scientific: Injunction against sales of Boston Scientific Express stents and 30% royalty payments to Medinol on Taxus drug-eluting stents applies only to The Netherlands, Hague district court rules. Court finds device infringes one Dutch counterpart of four European patents asserted by Medinol. Boston Scientific, which will appeal the decision, notes that "neither the injunction nor potential damages will be material," because total 2003 sales of the devices in The Netherlands will be only about $10.6 mil. Meanwhile, Medinol's request for cross-border relief in 16 European countries is denied. The ruling follows a June 24 Dusseldorf, Germany district court finding that Boston Scientific infringed Medinol patents in that country (1"The Gray Sheet" June 30, 2003, p. 22). Related New York federal court litigation between the firms is ongoing (2"The Gray Sheet" Dec. 8, 2003, p. 23)...
Litigation In Brief
Medinol v. Boston Scientific: Injunction against sales of Boston Scientific Express stents and 30% royalty payments to Medinol on Taxus drug-eluting stents applies only to The Netherlands, Hague district court rules. Court finds device infringes one Dutch counterpart of four European patents asserted by Medinol. Boston Scientific, which will appeal the decision, notes that "neither the injunction nor potential damages will be material," because total 2003 sales of the devices in The Netherlands will be only about $10.6 mil. Meanwhile, Medinol's request for cross-border relief in 16 European countries is denied. The ruling follows a June 24 Dusseldorf, Germany district court finding that Boston Scientific infringed Medinol patents in that country (1"The Gray Sheet" June 30, 2003, p. 22). Related New York federal court litigation between the firms is ongoing (2"The Gray Sheet" Dec. 8, 2003, p. 23)...
Financings In Brief
Baxter/Cerus: Baxter Capital Corporation aims to recall a $50 mil. loan to Cerus through legal proceedings, alleging that the firm's recent termination of Phase III clinical trials for the Intercept pathogen inactivation system for red blood cells constitutes default under the terms of the credit facility (1"The Gray Sheet" Sept. 8, 2003, p. 14). Cerus disagrees, asserting that interest and principle on the loan, which commenced in January, are not due until 2008. Cerus also notes it is cutting its current workforce by about 40 people, or roughly 25%, and R&D expenses for 2003 by approximately $5-$10 mil. The move will produce $20-$25 mil. in projected 2004 savings. The firms' relationship in developing Intercept for platelets is unaffected by the financing issue, Cerus says...